Navigation Links
Drug prevents bone loss side effects of breast cancer medication
Date:10/9/2011

A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that some breast cancer patients could take zoledronic acid in addition to their anti-cancer medications to maintain bone health.

Drugs called aromatase inhibitors stop the production of estrogen in postmenopausal women and therefore make less estrogen available to stimulate the growth of certain breast cancer cells. Many postmenopausal women with breast cancer are routinely treated for several years with these potentially life-saving drugs, but the agents can cause bone loss and fractures.

Adam Brufsky, MD, PhD, of the University of Pittsburgh Cancer Institute, and his colleagues conducted a study to see if the bone drug zoledronic acid could prevent and treat bone loss in postmenopausal breast cancer patients. In their five-year study, called Z-FAST, 602 postmenopausal women with early breast cancer who were receiving the aromatase inhibitor letrozole were randomized to receive zoledronic acid simultaneously with letrozole or only after bone loss or fractures occurred.

The investigators observed significant and progressive increases in bone density throughout the five years of the study in women who initiated zoledronic acid at the start; in contrast, significant decreases in bone density occurred when zoledronic acid administration was delayed until bone loss was apparent. Over time, though, the rate of bone density decline in the delayed group slowed, most likely because more delayed patients received zoledronic acid by the end of the study. These findings indicate that bone density is maintained more effectively with upfront zoledronic acid, but bone loss is likely reversible so that initiating zoledronic acid, even after bone loss has developed, is beneficial.

"This study shows that bone loss from aromatase inhibitors can be prevented long term with a safe and effective drug that prevents osteoporosis," said Dr. Brufsky. Zoledronic acid is currently approved by the U.S. Food and Drug Administration for conditions including osteoporosis and bone complications of cancer.


'/>"/>

Contact: Jennifer Beal
healthnews@wiley.com
44-124-377-0633
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Knockout of protein prevents colon tumor formation in mice
2. Marijuana administration after a traumatic experience prevents post-traumatic stress symptoms
3. Adding a stent during minimally invasive surgery to repair aneurysms prevents recurrence
4. Tai Chi Prevents Falls, Boosts Mental Health in Seniors: Study
5. UNC-led study shows early treatment with antiretroviral therapy prevents HIV transmission
6. Tobacco-derived compound prevents memory loss in Alzheimers disease mice
7. Early infusion of donor T cells prevents graft versus host disease in blood cancer patients
8. Tomatoes found to contain nutrient which prevents vascular diseases
9. Finnish researchers find a compound that prevents the growth of prostate cancer cells
10. Researchers establish new rule to predict risk of stroke, death from surgery that prevents it
11. New discovery prevents symptoms of rare genetic disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: